摘要
目的探讨吡咯替尼联合TCbH新辅助化疗方案治疗晚期HER-2阳性乳腺癌的近期疗效。方法选取晚期HER-2阳性乳腺癌患者90例,随机数字表法分为对照组、观察组,每组各45例,对照组接受TCbH新辅助化疗方案,观察组接受吡咯替尼联合TCbH新辅助化疗方案,治疗4个周期后评估近期疗效,分别于治疗前、治疗4个周期后采用电化学发光免疫法检测CEA、CA153、TPS水平,应用流式细胞仪检测CD3^(+)、CD4^(+)、CD8^(+),并于治疗期间统计不良反应情况。结果两组近期疗效比较,P>0.05。观察组肿瘤标志物水平均低于对照组(P<0.05),CD3^(+)、CD4^(+)水平、腹泻、手足综合征发生率均高于对照组(P<0.05)。结论吡咯替尼联合TCbH新辅助化疗方案治疗晚期HER-2阳性乳腺癌疗效良好,但可能会引起腹泻和手足综合征等不良反应。
Objective To investigate the short-term efficacy of pyrrolizinib combined with TCbH neoadjuvant chemotherapy in the treatment of advanced HER-2 positive breast cancer.Methods A total of 90 patients with advanced HER-2 positive breast cancer were selected and randomly divided into the control group and the observation group,45 cases in each group.The control group received TCbH neoadjuvant chemotherapy,and the observation group received pyrrolizinib combined with TCbH neoadjuvant chemotherapy.The levels of CEA,CA153 and TPS were detected by electrochemiluminescence immunoassay before treatment and after 4 cycles of treatment,and the levels of CD3^(+),CD4^(+)and CD8^(+)were detected by flow cytometry.The adverse reactions during treatment were counted.Results The short-term efficacy was compared between the 2 groups(P>0.05).The levels of tumor markers in the observation group were lower than those in the control group(P<0.05),the levels of CD3^(+)and CD4^(+),and the incidences of diarrhea and hand-foot syndrome were higher than those in the control group(P<0.05).Conclusion Pyrroitinib combined with TCbH neoadjuvant chemotherapy is effective in the treatment of HER-2 positive breast cancer,but it may cause diarrhea and hand-foot syndrome and other adverse reactions.
作者
李静
朱九荣
王征
LI Jing;ZHU Jiurong;WANG Zheng(Nanyang Central Hospital,Nanyang,473000)
出处
《实用癌症杂志》
2025年第4期646-649,共4页
The Practical Journal of Cancer
